OKYO Pharma is a clinical-stage biopharmaceutical company developing next-generation treatments for inflammatory eye diseases and ocular pain, with a focus on targeting a novel G Protein-Coupled Receptor class (ChemR23/CMKLR1) involved in ocular inflammation and pain pathways. The company's lead candidate, urcosimod, is a lipidated peptide designed to block ChemR23 signaling; it is being developed primarily for neuropathic corneal pain—a debilitating condition with no FDA-approved topical treatments—and previously showed efficacy in a Phase 2b trial in dry eye disease patients. OKYO generates revenue through upfront licensing agreements and milestone payments from patent agreements with academic and biotech partners, while advancing clinical trials toward potential regulatory approval and future commercialization of its therapeutic pipeline.